Yabao Pharmaceutical Group Co., Ltd (SHA:600351)

SHA:600351 Revenue

Yabao Pharmaceutical Group had revenue of 572.92M CNY in the quarter ending June 30, 2026, with 9.15% growth. This brings the company's total for the last twelve months to 2.25B, down -5.72% year-over-year. In the year 2025, Yabao Pharmaceutical Group had annual revenue of 2.24B, down -16.60%. That makes Yabao Pharmaceutical Group the 13,716th largest company in the world by revenue and 2,423rd in China.

• Revenue (ttm): 2.25B
• Revenue Growth: -5.72%
• P/S Ratio: 2.11
• Revenue / Employee: 657.57K
• Employees: 3,415
• Market Cap: 4.75B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Medical Production 1.80B 81.3%
• Wholesale of Medicine 389.76M 17.6%
• Other Trade 23.87M 1.1%

By Geography

Chart

• North China 738.00M 33.4%
• East China 415.99M 18.8%
• Central China Region 305.24M 13.8%
• Southwest Region 260.09M 11.8%
• Northwestern Region 191.09M 8.6%
• Southern China 155.60M 7.0%
• Northeast China Region 136.95M 6.2%
• Export 7.08M 0.3%

Fiscal year ended Dec 31, 2025 See the full SHA:600351 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.24B	-445.97M	-16.60%
Dec 31, 2024	2.69B	-223.73M	-7.69%
Dec 31, 2023	2.91B	191.63M	7.05%
Dec 31, 2022	2.72B	-45.83M	-1.66%
Dec 31, 2021	2.76B	161.54M	6.21%

Data Source: S&P Global Market Intelligence Last updated: Jul 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error